Management of Bone Disease and Body Composition Changes

  • Author: Donald P. Kotler, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 5/7/18 (What's New)

Summary

  • Use of the thymidine analogue NRTIs that are associated with lipoatrophy has waned in favor of NRTIs that are more tolerable, such as tenofovir DF, abacavir, and tenofovir AF
  • Many clinicians agree that prevention of lipoatrophy is a better practice than trying to reverse the process once it is clinically evident

Action required

Keywords: Fat Perturbations, Initial Antiretroviral Therapy, Switch Strategies, Treatment Complications

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.